Men with prostate cancer are reported as commonly using complementary and alternative medicine (CAM) but surveys have not recently been subjected to a rigorous systematic review incorporating quality assessment. Six electronic databases were searched using pre-defined terms. Detailed information was extracted systematically from each relevant article. Study reporting quality was assessed using a quality assessment tool, which demonstrated acceptable inter-rater reliability and produces a percentage score. In all, 42 studies are reviewed. All were published in English between 1999 and 2009; 60% were conducted in the United States. The reporting quality was mixed (median score ¼ 66%, range 23-94%). Significant heterogeneity precluded formal meta-analysis. In all, 39 studies covering 11 736 men reported overall prevalence of CAM use; this ranged from 8 to 90% (median ¼ 30%). In all, 10 studies reported prevalence of CAM use specifically for cancer care; this ranged from 8 to 50% (median ¼ 30%). Some evidence suggested CAM use is more common in men with higher education/incomes and more severe disease. The prevalence of CAM use among men with prostate cancer varies greatly across studies. Future studies should use standardised and validated data collection techniques to reduce bias and enhance comparability.
Introduction
Prostate cancer is the most prevalent cancer among men in the Western hemisphere. Since the advent of PSA testing, detection and hence incidence of prostate cancer have increased and earlier (and improved) treatments have led to decreased mortality. [1] [2] [3] Initial treatment options for men with localised prostate cancer in the United Kingdom are: watchful waiting, active surveillance, radical prostatectomy, external beam radiotherapy, brachytherapy, high intensity focused ultrasound and cryotherapy. 4 However, there is a paucity of high quality evidence comparing these treatments to guide patients and clinicians in their treatment choices 5 and adverse effects including impotence are common, persistent and associated with reduced quality of life. 6, 7 Men with prostate cancer may choose to supplement their conventional treatment with one or more forms of complementary or alternative medicine (CAM).
The National Center for Complementary and Alternative Medicine defines CAM as 'a group of diverse medical and health care systems, practises and products that are not generally considered part of conventional medicine' 8 and identifies five groups of such interventions: whole-medical systems (e.g. Ayurveda), mindbody medicine (e.g. meditation), biologically based practices (e.g. dietary supplements), manipulative and body-based practices (e.g. chiropractic) and energy medicine (e.g. Reiki). Of the biologically based practices, saw palmetto is particularly well known for prostate health and its popularity has generated both safety and efficacy research. 9, 10 The patented dietary supplement PC-SPES was promoted for and became particularly popular among men with prostate cancer; this induced trials that reported both beneficial and adverse effects. [11] [12] [13] Safety concerns were then raised that led to the eventual withdrawal of PC-SPES in the United States owing to contamination (see the National Cancer Institute for summary 14 ) . Since the withdrawal of PC-SPES, large-scale studies have been carried out on other biologically based practices for prostate health, notably the SELECT trial of vitamin E and selenium for cancer prevention. 15 Surveys on CAM use in prostate cancer have not recently been subjected to a rigorous systematic review incorporating quality assessment. Previous reviews on the subject need up-dating and do not provide detailed information focused on CAM use in prostate cancer. [16] [17] [18] Currently, this makes it difficult to have confidence in assertions about the prevalence of CAM use in prostate cancer. Furthermore, a comprehensive up-to-date review would provide useful information for oncologists that could aide their communication with patients about CAM, inform the research community as to gaps and inconsistencies in this literature and possibly identify new research areas. We therefore, carried out a systematic review of surveys on CAM use by men with prostate cancer. Our primary aims were: to evaluate the prevalence of use of CAM overall and of specific CAM modalities. Our secondary aims were: to assess the methodological quality of the surveys; to explore the consistency of findings regarding factors associated with CAM use (clinical and demographic characteristics and study characteristics, such as date, geographical location and quality), and to explore common reasons for CAM use.
Methods

Literature search
Our search strategy was designed to identify primary research studies investigating the prevalence of CAM use (i.e. surveys). Studies examining the outcomes of specific therapies (e.g. clinical trials and cohort studies) were excluded, as were qualitative studies. We included full publications published in journals and excluded the 'grey' literature (e.g. conference proceedings or letters). Six electronic databases were searched for articles meeting the above criteria: Medline (1950-06/ 09), AMED (1985-06/09), CINAHL (1982-06/09), EMBASE (1980-06/09), PsychINFO (1985-06/09), Web of Science (1970-06/09). We have described our pre-specified search strategies elsewhere. 19 In brief, we used the following medical subject headings terms plus free-text equivalents as required for each database: 'complementary therapies (exploded)' AND 'neoplasms (exploded)' AND 'data collection (exploded)'. We used End Note Web 2.2 to organise the identified references. Titles and abstracts were reviewed for eligibility. If these contained insufficient information, the complete article was obtained. We did not restrict our searches by language, but did not identify any eligible non-English language papers.
Data extraction and quality assessment
Detailed information related to data collection and results was extracted systematically from each paper and entered into a pre-designed Excel spreadsheet.
We used a quality assessment tool (QAT) for surveys initially developed in the context of a systematic review of CAM use in paediatric cancer, 19 which demonstrated good inter-rater reliability. This tool was based on the specific checklist for cross-sectional studies of the Strengthening the Reporting of Observational Studies in Epidemiology Statement. 20 For the present review, we removed two unnecessary items concerning patient gender and cancer diagnosis. In the resulting 15-item QAT, the original weighting of items was retained giving a maximum total score of 15.5 points. A percentage score was used as an indicator of overall reporting quality, as not all criteria apply to each paper. Scoring the papers (rather than merely describing their strengths and limitations) allowed us to explore more easily the relationship between reporting quality and outcomes. All papers were scored by two investigators and according to Cohen's Kappa the inter-rater reliability of all but one item was substantial (kappa above 0.6 21 ) or almost perfect (kappa above 0.8 21 ; Table 1 ); the overall scale had excellent inter-rater reliability (kappa ¼ 0.88).
A number of papers in our review reported on the prevalence of CAM use in prostate cancer and in other types of cancer or the general population. For these papers, data extraction focused exclusively on data specific to the subgroup of patients with prostate cancer. However, quality assessment was carried out considering the entire paper.
Statistical analyses
We used standard descriptive statistics and Forest plots to depict prevalence rates of overall CAM use and of specific CAM modalities. If studies reported multiple prevalence rates, the rate for CAM use since cancer diagnosis was selected. The relationships between prevalence rates and study-level factors (time, geographical location and quality) were explored graphically. The relationships between CAM use and patient-level factors (sociodemographic and clinical characteristics) were explored by examining findings across studies. Too few studies reported sufficient information consistently to allow more formal statistical analyses. Furthermore, owing to the heterogeneity of the included data we were unable to pool prevalence data in a meta-analysis.
Results
Study selection and characteristics
We identified 2311 unique references (after removing 753 duplicates), of which 297 reported on the prevalence of CAM use by patients with any type of cancer. We excluded 255 studies as they reported CAM use either in other specific cancer populations (e.g. breast cancer and colorectal cancer) or in undifferentiated cancer populations (i.e. a study may have surveyed men with prostate cancer, but not reported the prevalence of CAM use in this group alone). In all, 42 studies reported on the prevalence of CAM use among men with prostate cancer, and are included in this review. However, only 17 of these studies focused exclusively on men with prostate cancer. 22, 24, 28, 29, 34, 36, 37, 39, 40, 50, 51, 54, 56, [58] [59] [60] 62 The remaining studies collected data from broader study populations and reported the prevalence of CAM use for subgroups including men with prostate cancer. 23, [25] [26] [27] [30] [31] [32] [33] 35, 38, [41] [42] [43] [44] [45] [46] [47] [48] [49] 52, 53, 55, 57, 61, 63 The characteristics of all 42 included studies are summarised in Table 2 ). In all, 13 studies reported some information about the stage of cancer at diagnosis, including clinical stage, Gleason score, presence of metastases and/ or PSA levels. 22, 28, 34, 36, 40, 45, 50, 51, 53, [58] [59] [60] 62 The variety of indicators used and statistics reported (e.g. percentages, means), precludes any meaningful summary of this data, but Table 2 describes the disease characteristics of participants as reported in each study. In all, 16 studies reported the conventional medical treatments used by their participants for prostate cancer. 22, 23, 25, 28, 29, 34, 35, 37, 40, 50, 54, 56, [58] [59] [60] 62 These findings are summarised in Table 3 . In all, 16 studies reported the participants' age. 22, 28, 29, 34, 35, 37, 40, 50, 51, 53, 54, 56, [58] [59] [60] 62 Mean age ranged from 61.5 56 to 70 years 59 in 15 studies. In all, 13 studies reported some information about the educational level of their participants. 22, 28, 29, 35, 39, 51, 53, 54, 56, [58] [59] [60] 62 High school was completed by 73% 60 to 96% 51 of participants in 12 studies.
Reporting quality
Reporting quality was mixed and total QAT scores ranged from 23 to 94% (median ¼ 66%) (Table 1) In summary, the included literature was adequate for assessing and reporting prevalence of specific CAM modalities; clearly defining CAM both in the paper and for the survey respondents; reporting participants' characteristics, in particular age and SES indicators;
reporting response rates. The weaknesses we identified were: common use of data collection strategies that are subject to recall bias (i.e. that ask participants to recall their CAM use over a period of more than 12 months or that do not specify a recall period); lack of reporting of pilot testing of measures of CAM use; collecting data from samples that are unlikely to be representative of the general population of men with prostate cancer.
Prevalence of CAM use
Prevalence rates for overall use of CAM (as defined by individual studies) were reported in 39 studies including data on 11 736 men with prostate cancer. [22] [23] [24] [25] [26] [27] [28] [29] 31, 33, 34, Across these studies, the prevalence of CAM use ranged from 8 to 90%, while the interquartile range was 25-43% (median ¼ 30%). Sollner et al. 55 report the lowest prevalence rate (8%), but this is based on a very small sample size (n ¼ 12). Three of the four studies reporting prevalence rates above 60% focused on the use of dietary or nutritional supplements, 45, 54, 60 which are a broad class of therapies some of which (e.g. multivitamins) might now be considered conventional self-care rather than CAM. The other study reporting over 60% CAM use focused on the use of self-prayer for health 52 -the status of this practice as a form of CAM has also been questioned. 64 As shown in Figure 1 Points were awarded for each item on the quality assessment tool and a total score was then calculated for each study (as a %, see text for details). This enabled the reporting quality of individual studies to be summarised numerically for comparison and further analysis. Individual studies' total scores are reported in Table 2 . Complementary medicine use in prostate cancer FL Bishop et al Prevalence rates for use of specific CAM modalities were also reported by a number of studies. Here we focus on the five CAM modalities reported most frequently across studies (see Figure 2 ). In all, 11 studies reported prevalence of saw palmetto use among 6525 men; 22, 24, 28, 34, 36, 51, 54, 56, [58] [59] [60] 37 In all, 9 studies reported on use of vitamins among 1734 men; 29, 34, 35, 37, 40, 54, 56, 59, 62 this ranged from 3.6 62 to 79.3%. 54 These studies reported on use of vitamins as an overarching category that was not defined consistently by the authors and could include vitamin E and/or multivitamins. Eight studies reported on use of Vitamin E among 3261 men; 22, 28, 34, 36, 50, 51, 54, 60 this ranged from 5.0 28 to 53.3%. 54 
Factors related to CAM use
Visual inspection of scatter plots (not shown) suggested no simple relationship between prevalence of CAM use and study-level variables including sample size, study quality and geographical location. Figures 1 and 2 suggest that the prevalence of CAM use might have increased slightly over the past 10 years, although this trend was not statistically significant (Pearson's r (n ¼ 39) ¼ 0.25, P ¼ 0.12). The evidence concerning individual patient-level correlates of CAM use was also limited (see Table 4 ). From these studies it seems unlikely that CAM use among men with prostate cancer is strongly related to marital status or age. There was more consistent evidence to suggest that CAM use might be more likely among men with higher education or higher income, although again a number of studies fail to find significant associations. Similarly, there was some evidence that men with more severe or advanced cancer, assessed both at diagnosis and subsequently, might be more likely to use CAM. There was no clear relationship between overall study quality as assessed by the QAT and whether or not significant relationships were reported between CAM use and patient-level factors.
Common reasons for CAM use
Nine studies 22, 29, 34, 35, 37, 53, [57] [58] [59] reported on men's reasons for CAM use (Table 5) . A variety of reasons were either specifically asked about by investigators or offered by participants. Commonly reported reasons concerned physical health status (e.g. to treat cancer or side-effects) and psychological well-being (e.g. to gain a sense of control or hope). Less commonly endorsed reasons 'a broad domain of healing resources that encompasses all health systems, modalities, practices and their accompanying theories and beliefs, other than those intrinsic to the politically dominant health system of a particular society or culture in a given historical period' and 'therapies used along with conventional medicine that are non-invasive, pleasant, stress-reducing, and can be used in states of sickness or health.' (p 136)
Yoshimura et al. Overall prevalence of CAM use in relation to cancer is not reported (although use of specific modalities in relation to cancer care is reported).
d
Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into NCCAM categories, which are not mutually exclusive).
e Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into three non-mutually exclusive categories -use of CAM provider, use of dietary/nutritional supplement/use of other CAM therapy, some of which are further separated into use to treat cancer or prevent cancer recurrence).
f Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into specific individual CAM modalities which are not mutually exclusive).
g This figure is prevalence of CAM use since diagnosis. The paper also reports prevalence of CAM use in the past 3 months (2.6%).
Complementary medicine use in prostate cancer FL Bishop et al related to the respondent's social networks (e.g. recommendations from friends or health care staff).
Discussion
The primary studies that we have located and reviewed do not allow us to offer any definitive statements concerning the prevalence of CAM use among men with prostate cancer. Indeed, the prevalence of CAM use reported by individual studies ranged from 8 to 90%, and the high degree of heterogeneity in this literature precluded any formal meta-analysis. Previous reviews of the wider literature on CAM use across multiple cancer diagnoses have also found considerable variation across studies. 17, 18 The variation in prevalence rates may be a consequence of the varied definitions of CAM use utilised in the original studies. For example, in our primary studies the reported time period over which CAM use is assessed ranged from 'current' CAM use (presumably more akin to incidence than prevalence) through CAM use since diagnosis (a varied time for different participants)/over the past 4 weeks-12 months, to any CAM use ever. If we focus exclusively on the use of CAM as part of cancer care, then the prevalence of CAM use ranged from 8 to 50%. It is likely that men with prostate cancer not only use CAM for cancer care, but also for other reasons (e.g. general health and other conditions), and many of the studies included in this review did not clearly distinguish these two different types of CAM use. Lack of specificity regarding CAM use for cancer care was also encountered in our analysis of the prevalence of use of specific CAM modalities. The five CAM modalities examined most often in the original studies were saw palmetto, selenium, herbal medicine/ supplements in general, vitamins and vitamin E. It would seem that vitamins in general and vitamin E in particular are used more frequently than saw palmetto, selenium, or herbal medicine/supplements in general. Perhaps vitamin E is more widely available or cheaper than saw palmetto or selenium (income does appear to be associated with CAM use in this population), or perhaps the negative publicity surrounding PC-SPES has encouraged men to use vitamins instead of less well-known supplements. Some supplements have been investigated for prostate cancer prevention, 15, 65, 66 but clinical studies on their therapeutic use in prostate cancer are rare. 67 It will be interesting to see whether supplement use declines in this population, or if new supplements are sought out, as a result of major trials, such as SELECT. 15 At present, further research on the efficacy and safety of such approaches seems warranted given that patients are initiating and/or continuing to use supplements after cancer diagnosis and possibly alongside conventional treatments. Indeed, some of these CAMs have the potential to interact with conventional medical treatments in both beneficial and detrimental ways; 68 consequently oncologists need to encourage open dialogue about these interventions to understand whether and what kinds of CAM their individual patients are using.
We examined possible reasons for, and correlates of, CAM use by exploring men's reasons for CAM use as reported across studies, by assessing the consistency of evidence concerning clinical and demographic correlates Complementary medicine use in prostate cancer FL Bishop et al of CAM use and by exploring possible study-level correlates of CAM use. We were unable to determine with any specificity the most common reasons for CAM use across studies, or to examine how men's reasons for using CAM may differ over time and place. The use of standardised measures would make this possible in future. Only 9 out of the 42 studies reviewed reported men's reasons for using CAM; commonly reported reasons included wanting to improve or maintain physical health (related to prostate cancer and/or its conventional treatment) and psychological well-being and outlook. The variety in prevalence rates reported across our studies may be, at least in part, due to differences in participants' perceived unmet needs concerning their health and well-being. It may also be partly due to differences in the demographic or clinical characteristics across participants in the different studies: there was some evidence that men with higher educational achievements or higher incomes are more likely to use CAM, and that men with more severe or advanced cancer are more likely to use CAM. CAM use in the general population is also associated with higher education, but is less commonly associated with income and the evidence concerning clinical characteristics is mixed. 69 We found a weak trend for CAM use to have increased over the past 10 years; there was no clear pattern across other study-level factors (quality and location).
Overall, the quality of the studies was reasonable and, was on average, higher than the quality of studies in our recent review of CAM use in paediatric cancer (median QAT score 66 versus 50% 19 ). We identified common limitations that can be overcome in future studies by, firstly, asking participants to report their current CAM use that is associated with their cancer care (or by limiting recall periods to less than 12 months); secondly, using pilot-tested, validated and standardised questionnaires or interview protocols to measure CAM use (e.g. Refs 70, 71) ; and thirdly, collecting data from large, representative samples of men with prostate cancer identified from population-based registers or, at least, multiple treatment centres. Mao (2008) Porter (2008) CAM USE FOR CANCER:
Maskarinec (2000) Paltiel (2001) Metz (2001) Wilkinson (2002) Salmenpera (2002) Diefenbach (2003) Chan (2005) Wiygul (2005) Sheriff (2005) Vapiwala (2006) Wilkinson (2008) Corner (2009) Miller (2009) USE SINCE DIAGNOSIS:
Gotay (1999) Kao (2000) Jones (2002) Patterson (2002) Yoshimura (2003) Ponholzer (2003) Chrystal (2003) Lafferty (2004) Cheung (2004) Molassiotis (2005) Yoshimura (2005) Bruns (2006) Mao ( Complementary medicine use in prostate cancer FL Bishop et al Wilkinson (2008) Porter (2008) Chan (2005) Wiygul (2005) Sheriff (2005) Steginga (2004) Boon (2003) Diefenbach (2003) Hall (2003) Wilkinson (2002) Jones (2002) SAW PALMETTO:
Porter (2008) Wilkinson (2008) Chan (2005) Sheriff (2005) Wiygul (2005) Steginga (2004) Boon (2003) Diefenbach (2003) Ponholzer (2003) Jones (2002) Wilkinson (2002) SELENIUM:
Wilkinson (2008) Hann (2005) Sheriff (2005) Steginga (2004) Eng (2003) Hall (2003) Yoshimura (2003) Kao ( Miller (2009) Chan (2005) Hann (2005) Wiygul (2005) Eng (2003) Hall (2003) Yoshimura (2003) Jones (2002) Lee (2002) Kao (2000) Lippert ( All score 450% on QAT Higher (i.e. more) education 13 Seven studies (54%) The conclusions that can be drawn from this review are limited, primarily because of the heterogeneity and quality of the original studies and also by our review procedures. Although we searched six electronic databases using pre-defined search terms, it is possible that we may have missed relevant publications from other sources in particular if published in languages other than English. Similarly, studies from the United States in particular and the wider English-speaking world dominated our review and so our conclusions should not be generalised beyond these settings. We considered subgroup and sensitivity analyses to explore the heterogeneity of included data. However, we did not find convincing criteria for homogeneous subsets of studies suitable for pooled analyses such as meta-analysis.
Published surveys on the prevalence of CAM use in men with prostate cancer are generally of reasonable quality but future studies should use standardised data collection tools to decrease methodological heterogeneity and facilitate data pooling in future reviews. Men with prostate cancer do commonly use CAM as part of their cancer care, but the prevalence of use varies substantially across studies from 8 to 50%. This variation is still greater when taking into account studies that do not focus exclusively on CAM use for cancer care. Oncologists, CAM practitioners, and their patients should work towards facilitating open communication about using CAM contemporaneously with conventional prostate cancer care. To cure cancer, to prevent recurrence or spread of cancer, to increase life expectancy, to improve quality of life, to relieve symptoms in general, to have more control over recovery, to give hope, to play a more active role in recovery, to boost immune system, to help manage stress, to manage or treat side-effects of conventional treatment.
Common (by 25-50% of respondents in any one study)
To 'feel better', to improve general overall health, to slow disease progression, to have a greater sense of control over cancer, for psychological support, because it is completely safe.
Less common (by o25% of respondents in any one study)
Because of medical or scientific information, because friends had good experiences of CAM, wanted to experiment, recommended by health care professional, because of current poor health status, disappointed by or not satisfied with conventional treatment, healthcare staff disinterested, because it is giving good results, to manage specific cancer symptoms (e.g. pain, fatigue), to experience a more holistic approach, to have a more involved relationship with a practitioner, felt pressured by family or friends.
Abbreviation: CAM, complementary and alternative medicine.
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